Bonus BioGroup Ltd
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more
Bonus BioGroup Ltd - Asset Resilience Ratio
Bonus BioGroup Ltd (BBIXF) has an Asset Resilience Ratio of 10.04% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how Bonus BioGroup Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bonus BioGroup Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.90 Million | 10.04% |
| Total Liquid Assets | $3.90 Million | 10.04% |
Asset Resilience Insights
- Moderate Liquidity: Bonus BioGroup Ltd has 10.04% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bonus BioGroup Ltd Industry Peers by Asset Resilience Ratio
Compare Bonus BioGroup Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Bonus BioGroup Ltd (2013–2023)
The table below shows the annual Asset Resilience Ratio data for Bonus BioGroup Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 29.05% | $13.04 Million | $44.89 Million | +21.49pp |
| 2021-12-31 | 7.56% | $7.89 Million | $104.32 Million | -48.52pp |
| 2020-12-31 | 56.08% | $28.85 Million | $51.44 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $10.16 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $5.58 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $2.90 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.76 Million | -- |
| 2014-12-31 | 22.11% | $1.00 Million | $4.52 Million | -42.61pp |
| 2013-12-31 | 64.72% | $5.28 Million | $8.16 Million | -- |